Compare OSS & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSS | ARMP |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.0M | 199.7M |
| IPO Year | 2017 | 1996 |
| Metric | OSS | ARMP |
|---|---|---|
| Price | $5.86 | $3.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $19.00 | $17.50 |
| AVG Volume (30 Days) | ★ 795.1K | 113.6K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,027,382.00 | N/A |
| Revenue This Year | $26.62 | N/A |
| Revenue Next Year | $23.21 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 34.46 | N/A |
| 52 Week Low | $4.17 | $2.75 |
| 52 Week High | $20.88 | $14.98 |
| Indicator | OSS | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 20.07 | 40.49 |
| Support Level | N/A | N/A |
| Resistance Level | $14.36 | $4.07 |
| Average True Range (ATR) | 0.44 | 0.33 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 3.01 | 42.64 |
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.